Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, ALCHEMIST Chemo-IO Study
Inclusion Criteria
- Previously registered to A151216
- Central and/or local testing of EGFR with no EGFR exon 19 deletion or EGFR L858 R mutation (applicable to non-squamous patients only)
- Central and/or local testing of ALK with no ALK rearrangement (failed testing is considered negative) (applicable to non-squamous patients only)
- Central and/or local testing of PD-L1 immunohistochemistry (IHC) using one of the following assays: DAKO 22C3, DAKO 28-8, EIL3N or SP263 * Note: Local testing results of EGFR and ALK by a local Clinical Laboratory Improvement Act (CLIA) certified laboratory is acceptable. The report must indicate the result as well as the CLIA number of the laboratory that performed the assay. Local result of PD-L1 by DAKO 22C3, Dako 28-8, EIL3N or SP263 are acceptable for enrollment on A081801. Patients with local results for EGFR, ALK and PD-L1 still need to be registered to A151216 and follow all the submissions requirements but do NOT need to wait for the results to proceed to A081801 registration
- Completely resected stage IB (>= 4 cm), II or IIIA non-small cell lung cancer (NSCLC) (squamous or non-squamous) with negative margins (complete R0 resection). Patients will be staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) Staging Manual, 2010 * Note: Patients with pathologic N2 disease, completely resected, are eligible. However, patients known to have N2 disease prior to surgery are not eligible; guidelines do not recommend up-front surgery for this population
- Complete recovery from surgery. Registration to A081801 must be 30-77 days following surgery
- Human immunodeficiency virus (HIV)-infected patients with a history of Kaposi sarcoma and/or multicentric Castleman disease on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0-1
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin >= 8 gm/dl
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Exclusion Criteria
- No prior neoadjuvant or adjuvant therapy for current lung cancer diagnosis
- No prior allogeneic tissue/solid organ transplant
- Patients must NOT have uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of (non-infectious) pneumonitis that required steroids
- No active auto-immune disease that has required systemic treatment within the last 2 years (e.g., disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment
- Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done =< 7 days prior to registration is required
- No patients with a “currently active” second malignancy that is progressing or has required active treatment within the last 3 years. Participants with non-melanoma skin cancers or carcinoma in situ (e.g., breast carcinoma or cervical cancer in situ) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to pembrolizumab and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
Alaska
Anchorage
Fairbanks
Arizona
Gilbert
Kingman
Phoenix
Tucson
Arkansas
Ft. Smith
Hot Springs
Jonesboro
California
Anaheim
Antioch
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Concord
Davis
Duarte
Dublin
Emeryville
Fontana
Fremont
Fresno
Harbor City
Irvine
La Jolla
Long Beach
Los Angeles
Martinez
Marysville
Modesto
Mountain View
Oakland
Orange
Palo Alto
Panorama City
Rancho Cordova
Rancho Mirage
Redwood City
Richmond
Riverside
Rohnert Park
Roseville
Sacramento
San Francisco
San Jose
San Leandro
San Luis Obispo
San Marcos
San Mateo
San Rafael
Santa Clara
Santa Cruz
Santa Maria
Santa Rosa
South Pasadena
South San Francisco
Stockton
Sunnyvale
Truckee
Upland
Vacaville
Vallejo
Walnut Creek
Whittier
Woodland Hills
Colorado
Aurora
Boulder
Centennial
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Golden
Grand Junction
Greeley
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Connecticut
Derby
Fairfield
Greenwich
Guilford
Hartford
New Haven
North Haven
Orange
Stamford
Torrington
Trumbull
Waterbury
Waterford
West Haven
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Aventura
Fort Lauderdale
Fort Myers
Hollywood
Jacksonville
Miami Beach
Orlando
Pembroke Pines
Tampa
Georgia
Atlanta
Braselton
Duluth
Gainesville
Lawrenceville
Savannah
Snellville
Guam
Tamuning
Hawaii
Aiea
Ewa Beach
Honolulu
Lihue
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Glenview
Highland Park
Hines
Kewanee
Macomb
Mattoon
Maywood
Mount Vernon
New Lenox
O'Fallon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Silvis
Springfield
Swansea
Urbana
Yorkville
Indiana
Fort Wayne
Indianapolis
Michigan City
Mooresville
Richmond
South Bend
Terre Haute
Iowa
Ames
Boone
Cedar Rapids
Clive
Council Bluffs
Creston
Davenport
Des Moines
Fort Dodge
Jefferson
Marshalltown
Sioux City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Hays
Independence
Kansas City
Kingman
Lawrence
Liberal
Manhattan
McPherson
Newton
Olathe
Overland Park
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Bardstown
Corbin
Edgewood
Fort Thomas
Lexington
London
Louisville
Madisonville
Paducah
Shepherdsville
Louisiana
Alexandria
Baton Rouge
Covington
Houma
Kenner
New Orleans
Shreveport
Slidell
Maine
Augusta
Bangor
Belfast
Biddeford
Brewer
Norway
Rockport
Sanford
South Portland
Maryland
Annapolis
Baltimore
Bel Air
Cumberland
Gaithersburg
Glen Burnie
Kensington
Largo
Ocean Pines
Randallstown
Salisbury
Westminster
Massachusetts
Beverly
Boston
Brighton
Burlington
Gloucester
Milford
Peabody
Pittsfield
South Weymouth
Springfield
Winchester
Worcester
Michigan
Adrian
Alma
Alpena
Ann Arbor
Battle Creek
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
Farmington Hills
Flint
Gladwin
Grand Rapids
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Midland
Monroe
Muskegon
Niles
Norton Shores
Novi
Pontiac
Reed City
Rochester Hills
Royal Oak
Saginaw
Saint Joseph
Shelby Township
Southfield
Sterling Heights
Tawas City
Traverse City
Troy
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Park Rapids
Princeton
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Worthington
Wyoming
Mississippi
Columbus
Grenada
Hattiesburg
New Albany
Oxford
Southhaven
Missouri
Ballwin
Branson
Cape Girardeau
Columbia
Creve Coeur
Farmington
Jefferson City
Joplin
Kansas City
Lee's Summit
North Kansas City
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Concord
Londonderry
Manchester
New Jersey
Camden
Moorestown
Mount Holly
Paramus
Ridgewood
Voorhees
Westwood
New Mexico
Albuquerque
Rio Rancho
New York
Bay Shore
Bronx
Brooklyn
Buffalo
Cooperstown
Glens Falls
Lake Success
Nyack
Rochester
Stony Brook
Syracuse
North Carolina
Durham
Gastonia
Hendersonville
Pinehurst
Raleigh
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Ohio
Akron
Alliance
Beavercreek
Belpre
Boardman
Canton
Centerville
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Dublin
Findlay
Franklin
Gahanna
Greenville
Grove City
Kettering
Lancaster
Mansfield
Marietta
Marion
Mayfield Heights
Mount Vernon
Newark
Perrysburg
Portsmouth
Sandusky
Toledo
Troy
Warren
Warrensville Heights
Westerville
Wooster
Youngstown
Zanesville
Oklahoma
Lawton
Oklahoma City
Oregon
Baker City
Bend
Clackamas
Coos Bay
Corvallis
Grants Pass
Medford
Newberg
Ontario
Portland
Redmond
Pennsylvania
Allentown
Bethlehem
Bryn Mawr
Chadds Ford
Chambersburg
Doylestown
East Stroudsburg
Ephrata
Gettysburg
Hanover
Harrisburg
Hazleton
Lebanon
Media
Paoli
Philadelphia
Pittsburgh
Pottstown
West Reading
Wynnewood
York
South Carolina
Bluffton
Boiling Springs
Charleston
Easley
Gaffney
Greenville
Greer
Mount Pleasant
Seneca
Spartanburg
Union
West Columbia
South Dakota
Sioux Falls
Tennessee
Bristol
Kingsport
Memphis
Texas
Abilene
Amarillo
Baytown
Bryan
Dallas
Fort Worth
Houston
Nassau Bay
Richardson
Sugar Land
The Woodlands
Virginia
Bristol
Burke
Charlottesville
Fishersville
Lynchburg
Martinsville
McLean
Mechanicsville
Midlothian
Norfolk
Norton
Portsmouth
Richmond
South Hill
Suffolk
Washington
Aberdeen
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Issaquah
Kennewick
Lacey
Lakewood
Longview
Port Townsend
Poulsbo
Renton
Seattle
Sedro-Woolley
Shelton
Tacoma
Vancouver
Walla Walla
Yelm
West Virginia
Bridgeport
Charleston
Huntington
Martinsburg
Morgantown
Parkersburg
Wisconsin
Antigo
Appleton
Ashland
Brookfield
Burlington
Chilton
Chippewa Falls
Cudahy
Eau Claire
Franklin
Germantown
Grafton
Green Bay
Kenosha
La Crosse
Ladysmith
Marinette
Marshfield
Medford
Mequon
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oconto Falls
Oshkosh
Racine
Rhinelander
Rice Lake
Sheboygan
Stevens Point
Sturgeon Bay
Summit
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
Weston
Wisconsin Rapids
Wyoming
Cheyenne
Cody
Sheridan
PRIMARY OBJECTIVES:
I. To compare the disease free survival (DFS) and overall survival (OS) (dual primary endpoints) between combination pembrolizumab plus standard of care (Arm C) versus (vs.) standard of care (Arm A) in patients with stage IB-IIIA non-small cell lung cancer.
II. To compare the DFS and OS (dual primary endpoints) between sequential pembrolizumab following standard of care (Arm B) vs. standard of care (Arm A) followed by observation in patients with stage IB-IIIA non-small cell lung cancer.
SECONDARY OBJECTIVES:
I. To compare the DFS and OS between combination pembrolizumab with standard of care (Arm C) vs. sequential standard of care followed by pembrolizumab (Arm B) in patients with stage IB-IIIA non-small cell lung cancer.
II. To compare the adverse event rates and drug discontinuation rates due to adverse events with the addition of pembrolizumab plus standard of care (combination and/or sequential; Arms B and C) vs. standard of care alone (Arm A) as well as Arm B versus Arm C in patients with stage IB-IIIA non-small cell lung cancer.
III. To compare the DFS and OS between pembrolizumab plus standard of care (combination and/or sequential; Arms B and C) vs. standard of care alone (Arm A) by PD-L1 expression status (tumor proportion score [TPS] >= 50% vs TPS < 50%) in patients with stage IB-IIIA non-small cell lung cancer.
IV. To compare the DFS and OS between pembrolizumab plus standard of care (combination and/or sequential; Arms B and C) vs. standard of care alone (Arm A) in patients with stage IB-IIIA non-small cell lung cancer that receive at least 2 cycles of initial adjuvant chemotherapy.
QUALITY OF LIFE OBJECTIVES:
I. To compare patient-reported quality of life (QOL) one year after randomization as assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-Core (C)30 between patients randomized to receive adjuvant chemotherapy followed by pembrolizumab (Arm B), and those randomized to receive adjuvant chemotherapy + observation (Arm A).
II. To compare patient reported QOL one year after randomization as assessed by EORTC QLQ-C30 between patients randomized to receive adjuvant chemotherapy + pembrolizumab concomitantly (Arm C) and those randomized to receive adjuvant chemotherapy + observation (Arm A).
III. To compare patient-reported QOL at completion of chemotherapy as assessed by the EORTC QLQ-C30 between patients randomized to receive adjuvant chemotherapy + pembrolizumab concomitantly (Arm C) and those randomized to receive adjuvant chemotherapy + observation or adjuvant chemotherapy followed by pembrolizumab (Arms A and B combined).
IV. To present longitudinal trajectories by arm of patient-reported dyspnea and coughing as assessed by the EORTC QLQ-Lung Cancer (LC13).
CORRELATIVE SCIENCE OBJECTIVES:
I. To compare the DFS and OS with the addition of pembrolizumab (combination and/or sequential) to standard of care platinum-based adjuvant therapy (Arms B and C) vs standard of care (Arm A) in the PD-L1 subgroup of patients with PD-L1 expression status (>= 1% vs < 1%).
II. To compare the DFS and OS with the addition of pembrolizumab (combination and/or sequential) to standard of care platinum-based adjuvant therapy (Arms B and C) vs. standard of care (Arm A) by tumor mutational burden status (high vs. low) in patients with stage IB-IIIA non-small cell lung cancer.
III. To identify a cell-free deoxyribonucleic acid (cfDNA) marker associated with high-risk of recurrence and improved DFS and OS with the addition of pembrolizumab to standard adjuvant chemotherapy (Arms B and C).
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM A:
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
CONTINUANCE THERAPY: Patients then undergo observation.
ARM B:
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
CONTINUANCE THERAPY: Patients then receive pembrolizumab intravenously (IV) over 25-40 minutes on day 1. Treatment repeats every 21 days for 17 cycles or every 6 weeks for 16 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.
ARM C:
INITIAL THERAPY: Patients receive 1 of 4 platinum doublet regimens* based on the treating physician's choice and pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.
CONTINUANCE THERAPY: Patients then receive pembrolizumab IV over 25-40 minutes on day 1. Treatment repeats every 21 days for 13 cycles or every 6 weeks for 12 cycles (patients enrolled after 10/14/2020) in the absence of disease progression or unacceptable toxicity.
*ACCEPTABLE REGIMENS:
DOUBLET I: Patients receive cisplatin IV over 1-2 hours and pemetrexed IV over 10 minutes on day 1 of each cycle.
DOUBLET II: Patients receive carboplatin IV over 30 minutes and pemetrexed IV over 10 minutes on day 1 of each cycle.
DOUBLET III: Patients receive cisplatin IV over 1-2 hours on day 1 of each cycle and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 of each cycle.
DOUBLET IV: Patients receive carboplatin IV over 30 minutes and paclitaxel IV over 3 hours on day 1 of each cycle.
After completion of study treatment, patients are followed up at 6 weeks, then every 3 months for 2 years from randomization, every 6 months for years 2-4, and then annually for up to 10 years from randomization.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Alliance for Clinical Trials in Oncology
Principal Investigator
Jacob M. Sands
- Primary ID A081801
- Secondary IDs NCI-2020-00751
- Clinicaltrials.gov ID NCT04267848